Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kinisoquin
- Development stage
- Unknown
- Lead developer
- Quercis Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Kinisoquin is an orally administered small molecule antithrombotic drug candidate being developed by Quercis Pharma AG for the prevention of venous thromboembolism (VTE) in cancer patients, specifically those with pancreatic cancer. The formulation consists of isoquercetin (a quercetin glycoside) combined with vitamins B3 and C to optimize bioavailability and stability. Kinisoquin functions as a multi-target therapeutic, primarily inhibiting Protein Disulfide Isomerase (PDI), an enzyme essential for thrombus formation. It also modulates other pathways including VEGF, Tissue Factor, PD-L1, and TMEM176. Unlike standard anticoagulants, it prevents coagulation within the vascular system without significantly increasing the risk of bleeding.
- Brand names
- Kinisoquin
- Other names
- isoquercetinquercetin-3-glucosidequercetin3-glucosidequercetin 3-glucosidequercetin-3-O-glucosidequercetin3-O-glucosidequercetin 3-O-glucoside
02
Targets
P4HB (Protein disulfide-isomerase)VEGFA (Vascular endothelial growth factor A)TMEM176B (Transmembrane protein 176B)CD274 (Programmed cell death protein 1 ligand 1)F3 (Tissue factor)
Beyond the preview
Go deeper on Kinisoquin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kinisoquin.